Isis gets notices of allowance that significantly expand scope of key RNA Therapeutic patents
News posting on September 08, 2008 | Related to Alnylam Pharmaceuticals
Isis Pharmaceuticals, Inc, Alnylam Pharmaceuticals, Inc, and the companies’ joint venture Regulus Therapeutics LLC, announced that the United States Patent and Trademark Office (USPTO) has granted notices of allowance for two U S patent applications that further enhance the scope of Isis’ “Crooke” patent estate, which broadly covers RNA-containing therapeutics.
Source: PharmaBiz
